Therapeutic advances in medical oncology · 2026
Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pietroluongo Erica, De Placido Pietro, Buonaiuto Roberto, Caltavituro Aldo, Neola Giuseppe, Ottaviano Margaret, Tortora Marianna, Arpino Grazia, Palmieri Giovannella, De Angelis Carmine, Garassino Marina Chiara, Bianco Roberto, Servetto Alberto, Giuliano Mario
Аннотация
BACKGROUND: Platinum-based chemotherapy is the first-line treatment choice for advanced thymic epithelial tumors (TETs), with the expected objective response rate (ORR) ≈of 50% in thymoma and ≈20% in thymic carcinoma.
OBJECTIVE: To evaluate the impact of relative dose intensity (RDI) on first-line treatment outcomes in TET patients.
DESIGN: Retrospective cohort referred between 2016 and 2022 at the University of Naples Federico II, Italy.
METHODS: Advanced TETs treated with first-line platinum chemotherapy; RDI calculated as delivered/planned dose intensity and categorized as low (<85%) or high (⩾85%). Outcomes: ORR, time to next treatment (TTNT), overall survival (OS).
RESULTS: Thirty-three patients (15 thymoma, 18 carcinoma); 22 low RDI, 11 high RDI. RDI was not associated with ORR. High RDI showed longer TTNT (6.6 vs 5.0 months; p = 0.042) and numerically longer OS (86.4 vs 32.2 months; p = 0.361).
CONCLUSION: Maintaining ⩾85% RDI during first-line platinum chemotherapy may offer clinical benefits and warrants further validation in larger cohorts.
OBJECTIVE: To evaluate the impact of relative dose intensity (RDI) on first-line treatment outcomes in TET patients.
DESIGN: Retrospective cohort referred between 2016 and 2022 at the University of Naples Federico II, Italy.
METHODS: Advanced TETs treated with first-line platinum chemotherapy; RDI calculated as delivered/planned dose intensity and categorized as low (<85%) or high (⩾85%). Outcomes: ORR, time to next treatment (TTNT), overall survival (OS).
RESULTS: Thirty-three patients (15 thymoma, 18 carcinoma); 22 low RDI, 11 high RDI. RDI was not associated with ORR. High RDI showed longer TTNT (6.6 vs 5.0 months; p = 0.042) and numerically longer OS (86.4 vs 32.2 months; p = 0.361).
CONCLUSION: Maintaining ⩾85% RDI during first-line platinum chemotherapy may offer clinical benefits and warrants further validation in larger cohorts.